Pharma’s salesforce is suffering — what does version 2.0 look like?
PharmaVoice
MARCH 28, 2023
Ahead of turbulent market conditions, EY analyst Arda Ural encourages companies to rethink their sales strategy.
Sat.Mar 25, 2023 - Fri.Mar 31, 2023
59 
High-Tech Hubs and Specialty Pharma
Pharmaceutical Commerce
MARCH 30, 2023
With the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
The Power of Patient Preference in Shaping the Drug Delivery Market
MedCity News
MARCH 29, 2023
Demand for alternative drug delivery methods has the potential to reshape therapeutic markets and improve clinical outcomes. New innovations, especially oral alternatives, are poised to drive broad changes across the entire sector.
As deadly pathogen spreads, GSK throws a lifeline to Scynexis with $90M deal to market antifungal
Fierce Pharma
MARCH 30, 2023
As deadly pathogen spreads, GSK throws a lifeline to Scynexis with $90M deal to market antifungal aliu Thu, 03/30/2023 - 10:39
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Rapid microbiology testing market growth expected 2022 to 2027
European Pharmaceutical Review
MARCH 27, 2023
A report has predicted the rapid microbiology testing market size is estimated to grow at a compound annual growth rate (CAGR) of 9.31 percent between 2022 and 2027. According to the data, the market is forecasted to increase by $2,487.91 million. The research includes historic market data from 2017 to 2021, using 2022 as the base year. It covers various testing methods such as growth-based, nucleic-acid-based and viability-based.
Hipra’s Covid-19 booster gets EMA nod and enters an uncertain landscape
Pharmaceutical Technology
MARCH 31, 2023
The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March. Bimervax is a recombinant protein subunit vaccine, marketed by the Girona, Spain-based Hipra.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
BioNTech surprises analysts with low revenue guidance as COVID-19 vaccine demand wavers
Fierce Pharma
MARCH 27, 2023
BioNTech surprises analysts with low revenue guidance as COVID-19 vaccine demand wavers fkansteiner Mon, 03/27/2023 - 09:35
Generic manufacturers sign sublicences to produce long-acting HIV medicine
European Pharmaceutical Review
MARCH 31, 2023
The Medicines Patent Pool (MPP) has signed sublicence agreements with three generics manufacturers to produce generic versions of cabotegravir long-acting (LA) injectable for human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP). First sublicence agreement signed by MPP for a long-acting medicine Through the sublicences, the selected generic manufacturers will be able to develop, manufacture, and supply generic versions of cabotegravir LA for PrEP, in 90 countries, subject to requir
BioNTech targets infectious diseases for vaccine development
Pharmaceutical Technology
MARCH 28, 2023
Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. In its FY 2022 report, BioNTech has identified herpes simplex virus (HSV), malaria, and shingles as disease targets. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer.
How the EU’s New Data Laws Could Affect American Health Tech Companies
MedCity News
MARCH 26, 2023
In the EU, there is a widespread distrust of American tech companies, according to a recent conference presentation by an international healthcare lawyer. Because of this, the EU has established a number of new laws protecting its citizens’ data privacy and creating frameworks for the secure exchange of information — laws that American health tech companies will have to comply with if they do business in the EU.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries
Fierce Pharma
MARCH 27, 2023
Novo's high-dose Rybelsus win tees up regulatory filings—and new rivalries esagonowsky Mon, 03/27/2023 - 09:19
First immunotherapy recommended for advanced cervical cancer
European Pharmaceutical Review
MARCH 29, 2023
Pembrolizumab (Keytruda) has been recommended in National Institute for Health and Care Excellence (NICE) final draft guidance for advanced cervical cancer. A promising immunotherapy “Pembrolizumab shows promise as the first effective immunotherapy [for advanced cervical cancer]” “Pembrolizumab shows promise as the first effective immunotherapy” for the condition, stated Helen Knight, Director of Medicines Evaluation at NICE.
Viking’s weight loss drug enters an already crowded arena
Pharmaceutical Technology
MARCH 29, 2023
Viking Therapeutics has announced the start of a Phase I clinical study to evaluate its dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist VK2735. The trial, which is investigating healthy adults with a minimum body mass index of 30 kg/m2, will see VK2735 administered as an oral tablet once daily for 28 days.
At ViVE, How Did VCs Respond to Criticism of Their Industry?
MedCity News
MARCH 29, 2023
The financial outlook for the digital health sector is less than ideal, characterized by lower funding amounts, shrinking valuations, dwindling profitability and the collapse of Silicon Valley Bank. During a recent conference panel, four healthcare VCs discussed their reactions to this. They explained why the market has switched its focus from growth to value, as well gave advice to startups about what they need to know in this changing environment.
Duo no more: After M&A spree, Pfizer parts ways with Merck KGaA on Bavencio
Fierce Pharma
MARCH 27, 2023
Duo no more: After M&A spree, Pfizer parts ways with Merck KGaA on Bavencio zbecker Mon, 03/27/2023 - 17:42
Nasal spray for depression shows long-term efficacy
European Pharmaceutical Review
MARCH 27, 2023
Adults with treatment-resistant major depressive disorder (TRD) treated with SPRAVATO ® ▼ (esketamine nasal spray [NS]) achieved significantly higher remission rates compared to those given quetiapine extended-release (XR), long-term Phase III study data has shown. The results from Janssen’s ESCAPE-TRD Phase IIIb trial presented at the European Congress of Psychiatry (EPA) 2023 indicated that esketamine NS achieved significantly higher remission rates from Week 6 and response rates as early as D
Nanoparticles Get Lymphatic Vessels Pumping
Medgadget
MARCH 27, 2023
Researchers at the Georgia Institute of Technology have developed a nanotechnological solution for lymphedema, a failure of the lymphatic system that results in uncomfortable and irreversible fluid retention. Previous research efforts have focused on trying to grow new lymphatic vessels, but these researchers have taken a different approach, and instead engineered a drug delivery technology that can directly target sluggish lymphatic vessels and kickstart their pumping action.
Too Many Dashboards, Not Enough Insight: How Companies Can Build Remote Patient Monitoring Tech
MedCity News
MARCH 26, 2023
To build remote patient monitoring technology for ready adoption, repetitive data streams must be avoided. To be successful in clinical adoption, we offer technology companies the following three recommendations.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
With FDA nod for a Novartis castoff, Pharming is set to market a second rare disease drug
Fierce Pharma
MARCH 27, 2023
With FDA nod for a Novartis castoff, Pharming is set to market a second rare disease drug kdunleavy Mon, 03/27/2023 - 10:40
SCOTUS to decide ‘fundamental change’ in biologics patents with fate of Amgen v. Sanofi
PharmaVoice
MARCH 28, 2023
The Supreme Court will now decide whether Amgen can protect Repatha as a whole class of drugs or whether Sanofi’s rival product Praluent can retain a place in the market.
Biopharma could reap benefits from SVB UK acquisition
European Pharmaceutical Review
MARCH 31, 2023
“The access to increased capital… could allow for the potential for biopharmaceutical companies to improve investment in the development of therapies.” Following the collapse of Silicon Valley Bank (SVB), HSBC’s acquisition of Silicon Valley Bank (SVP) UK may offer new opportunities for biopharmaceutical companies, according to data and analytics firm, GlobalData.
When It Comes to Radiology, What Can We Teach ChatGPT ?
MedCity News
MARCH 30, 2023
The potential of ChatGPT is exciting. Radiologists have come a long way on the AI journey. What started as a fear from some that AI would replace us, has evolved to a more nuanced understanding that AI’s greatest contribution in medical imaging is to make us better radiologists.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026: Moody's
Fierce Pharma
MARCH 30, 2023
Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026: Moody's kdunleavy Thu, 03/30/2023 - 07:28
Regenerative medicine: new focus on VEGF target?
Pharmaceutical Technology
MARCH 27, 2023
Regenerative medicines in early-stage development (preclinical, discovery, or investigational new drug [IND]/ clinical trial application [CTA] filed status) have seen a change in drug targets compared to therapies in late-stage development (Phase II to pre-registration stage). According to GlobalData’s Drugs database, early-stage therapies are focused on vascular endothelial growth factor (VEGF) as the top drug target, with three drugs currently in development.
Innovative mass spectrometry method facilitates accurate C. auris identification
European Pharmaceutical Review
MARCH 31, 2023
An innovative liquid chromatography (LC)—high resolution mass spectrometry method could quickly and correctly identify all Candida auris isolates with 99.6 percent confidence, a study has shown. Mass spectrometry (MALDI-TOF) has entered many clinical microbiology laboratories during the past decade. It has gradually replaced biochemical methods as the preferred tool for pathogen identification, the researchers noted.
It’s Time to Raise Our Voice for Interpreter Reimbursement in Healthcare
MedCity News
MARCH 29, 2023
As many as 25 million Americans over the age of five say they speak English “less than well” — that’s nearly a tenth of the country. Contrast that with the fact that nearly one third of American hospitals don’t provide interpreters to patients who speak little English, even though it is required by federal law. Only 13 states and Washington, D.C. provide reimbursements for the cost of medical interpreters through Medicaid.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications
Fierce Pharma
MARCH 29, 2023
Boehringer Ingelheim and Eli Lilly's Jardiance gets big lift from heart failure indications kdunleavy Wed, 03/29/2023 - 10:40
Progressive Medical, Inc. Awarded Drug Reconstitution and Transfer Devices Agreement with Premier, Inc. | Yukon
Progressive Medical
MARCH 28, 2023
Progressive Medical Awarded National Agreement with Premier Inc. PMI is pleased to announce that it has been awarded a […] The post Progressive Medical, Inc. Awarded Drug Reconstitution and Transfer Devices Agreement with Premier, Inc. | Yukon appeared first on Progressive Medical, Inc.
GSK to exclusively license novel oral antifungal
European Pharmaceutical Review
MARCH 30, 2023
GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme (ibrexafungerp tablets) for vulvovaginal candidiasis (VVC) from SCYNEXIS. The exclusive licence agreement will enable GSK to commercialise Brexafemme for VVC and recurrent VVC (RVVC). Currently, the treatment is in Phase III clinical trials for invasive candidiasis (IC).
How To Restore the Skin’s Microbiome From Over-sanitizing
MedCity News
MARCH 28, 2023
While alcohol-based hand sanitizers are very useful in settings where there is an increase in the transmission of pathogens (such as hospitals), there are no additional health benefits to habitual hand sanitizing unless a person doesn’t have access to running water.
Let's personalize your content